Douglas S W, Adamson J W
Division of Hematology, University of Washington School of Medicine, Seattle.
Blood. 1975 Jan;45(1):55-65.
Marrow regulation and iron metabolism were evaluated in 17 patients with mild or moderate anemia associated with chronic disorders. In addition, whole blood P50 and red cell 2,3-diphosphoglycerate (DPG) levels were measured. The study group consisted of seven patients with non-hematologic malignancies, nine with infection or inflammation, and one with idiopathic hypoproliferative anemia. The mean whole blood P50 and DPG levels were elevated to 28.5 +/- 1.9 mm Hg and 7.03 +/- 0.83 mumole/ml packed RBC, respectively, as compared to normal values of 26.6 +/- 0.6 mm Hg and 4.83 +/- 0.33 mumole/ml packed RBC. Erythropoietin (ESF) excretion was variable (1.1-28.7 IRP U, day), clearly elevated above normal in only three patients and, within the study group, bore no relation to hematocrit. While nine of the 17 subjects had ESF excretion rates within the 95% limits predicted by hematocrit, the remaining eight had lower than expected values. No significant differences in ferrokinetics, ESF excretion, or hematologic profile were found between patients with malignancy and those with inflammation. Marrow transit times correlated inversely with both serum and urine ESF activity (r = -0.57, p less than 0.02; and r = -0.63, p less than 0.01, respectively), indicating that the marrow reticulocyte release response to ESF stimulation was unimpaired. Erythroid iron turnovers were unrelated to serum or urinary ESF activity but were significantly correlated with serum iron levels expressed as microgram/100 ml whole blood (r = 0.56, p less than 0.02). These studies suggest that there is an intraerythrocytic response to the anemia in this group of patients, document that reduced ESF production is not a uniform finding with the anemia of chronic disorders, and provide evidence that the marrow proliferative response to anemia is limited in many patients primarily by the availability of iron.
对17例伴有慢性疾病的轻、中度贫血患者的骨髓调节和铁代谢进行了评估。此外,还测量了全血P50和红细胞2,3 - 二磷酸甘油酸(DPG)水平。研究组包括7例非血液系统恶性肿瘤患者、9例感染或炎症患者以及1例特发性增生低下性贫血患者。与正常全血P50值26.6±0.6 mmHg和红细胞压积4.83±0.33 μmol/ml相比,平均全血P50和DPG水平分别升高至28.5±1.9 mmHg和7.03±0.83 μmol/ml红细胞压积。促红细胞生成素(ESF)排泄量各不相同(1.1 - 28.7 IRP U/天),仅3例明显高于正常,且在研究组内,与血细胞比容无关。17例受试者中有9例的ESF排泄率在根据血细胞比容预测的95%范围内,其余8例低于预期值。恶性肿瘤患者与炎症患者在铁动力学、ESF排泄或血液学特征方面未发现显著差异。骨髓转运时间与血清和尿液ESF活性均呈负相关(分别为r = -0.57,p < 0.02;r = -0.63,p < 0.01),表明骨髓网织红细胞对ESF刺激的释放反应未受损。红系铁周转率与血清或尿液ESF活性无关,但与以微克/100 ml全血表示的血清铁水平显著相关(r = 0.56,p < 0.02)。这些研究表明,该组患者对贫血存在红细胞内反应,证明ESF生成减少并非慢性疾病贫血的普遍表现,并提供证据表明许多患者对贫血的骨髓增殖反应主要受铁供应的限制。